BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results, Meets Expectations

BioCryst Pharmaceuticals (NASDAQ:BCRX) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07), Briefing.com reports. The company had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. BioCryst Pharmaceuticals’s revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.19) EPS.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX traded down $0.11 during trading on Tuesday, reaching $7.24. The stock had a trading volume of 1,236,664 shares, compared to its average volume of 2,966,223. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88. The firm’s fifty day moving average is $7.84 and its 200 day moving average is $6.95. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -11.87 and a beta of 1.89.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BCRX shares. JMP Securities boosted their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $14.67.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.